Janney Montgomery Scott LLC Reduces Investment in United Therapeutics Co.
October 27, 2023
☀️Trending News
Janney Montgomery Scott LLC recently announced that it has reduced its investment in United Therapeutics ($NASDAQ:UTHR) Co. United Therapeutics is a U.S. biotechnology company that develops, manufactures, and commercializes innovative treatments for serious and life-threatening conditions. With their focus on the development of products and therapies that address unmet medical needs, United Therapeutics works to help improve the lives of patients suffering from various diseases, such as pulmonary arterial hypertension and cancer. United Therapeutics has a strong portfolio of proprietary therapeutic products and development programs for several other diseases.
In addition, United Therapeutics has numerous partnerships and collaborations with other pharmaceutical companies to develop additional therapies. The investment reduction by Janney Montgomery Scott LLC, though significant, is not expected to have a major impact on United Therapeutics’ operations or stock performance in the near future. The company continues to be committed to the development of new therapies for serious medical conditions and is confident that its products and services will continue to be in demand.
Market Price
On Monday, Janney Montgomery Scott LLC made a reduction to their investment in United Therapeutics Co. The stock opened at $223.9 and closed at $224.2, 0.6% lower than the prior closing price of $225.4. This reduction in investment caused the stock to dip in value, likely as a result of Janney Montgomery Scott LLC’s decision to move away from United Therapeutics Co. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for United Therapeutics. More…
| Total Revenues | Net Income | Net Margin |
| 2.11k | 871.5 | 41.3% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for United Therapeutics. More…
| Operations | Investing | Financing |
| 867.9 | -731.6 | 135.8 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for United Therapeutics. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 6.68k | 1.27k | 115.34 |
Key Ratios Snapshot
Some of the financial key ratios for United Therapeutics are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 13.8% | 25.2% | 55.4% |
| FCF Margin | ROE | ROA |
| 31.9% | 13.9% | 10.9% |
Analysis
GoodWhale has performed an analysis on UNITED THERAPEUTICS‘s wellbeing. Our Star Chart classifies UNITED THERAPEUTICS as a ‘gorilla’, which we conclude is a type of company that has achieved stable and high revenue or earning growth due to its strong competitive advantage. Investors looking for a strong company that can pay off debt and fund future operations may be interested in UNITED THERAPEUTICS. We assess UNITED THERAPEUTICS’s health score to be 9/10 in terms of its cashflows and debt. Furthermore, UNITED THERAPEUTICS is strong in asset, profitability, and medium in growth and weak in dividend. All of these factors make UNITED THERAPEUTICS an attractive investment option for many investors. More…
Peers
The company’s main competitors are MannKind Corp, Sanofi SA, Eli Lilly and Co.
– MannKind Corp ($NASDAQ:MNKD)
MannKind Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapeutics for diabetes and cancer. Its product pipeline includes Afrezza, MK-1293, and MK-3655. The company was founded by Alfred E. Mann on February 3, 1991 and is headquartered in Valencia, CA.
– Sanofi SA ($OTCPK:SNYNF)
Sanofi has a market cap of 98.97B as of 2022 and a Return on Equity of 7.56%. The company is a French multinational pharmaceutical company headquartered in Paris, France, and was founded in 1904. Sanofi is engaged in the research, development, manufacturing, and marketing of pharmaceutical products for the treatment of patients in the areas of cardiovascular, central nervous system, diabetes, internal medicine, oncology, and thrombosis.
– Eli Lilly and Co ($NYSE:LLY)
Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism.
The company’s market cap is $312.67 billion as of 2022 and its return on equity is 45.88%.
Summary
Analysts have suggested that the strong performance may be attributed to the company’s continued focus on developing innovative therapies for rare diseases, as well as its successful collaborations with other leading biotechnology and pharmaceutical companies. Investors should continue to closely monitor United Therapeutics‘ performance given its potential to continue producing innovative treatments and drugs that could benefit patients with rare diseases.
